Home> #BIGDATAFORBLOODCANCER campaign for patients/general audience: september 2021 - July 2022> Big data to improve the care for people with Leukemia

Big data to improve the care for people with Leukemia

August 24, 2021 12:00 - x 00, 0 - 00:00

#bigdataforbloodcancer, Leukemia

The HARMONY Alliance aims to improve the care for people with Leukemia. We have created a unique Big Data Platform with > 90.000 anonymized European patient records. Our partnership with more than 100 organizations will accelerate blood cancer research.

HARMONY Big Data Analytic tools are used to enable doctors to rapidly select the most promising treatment strategy for an individual patient. In addition, we develop Core Outcome Sets for blood cancers and organize activities for various audience groups in the blood cancer field. The active involvement of patient organizations ensures that our work is well-aligned with the needs of patients with leukemia.

Patients involved

Among HARMONY’s partners are 9 European patient umbrella organizations, the HARMONY Patient Cluster, including Leukanet, Acute Leukemia Advocates Network (ALAN), CCI Europe/Childhood Cancer International, CLL Advocates Network (CLLAN), CML Advocates Network, Lymphoma Coalition, International MDS Alliance, Myeloma Patients Europe (MPE) and MPN Advocates Network. Our patient advocates and their patient communities are involved in defining Core Outcomes Sets, designing Research Projects and interacting with patients and their families.

Our activities in Leukemia

Our Focus

ALL: Acute Lymphoblastic Leukemia >
AML: Acute Myeloid Leukemia >
CML: Chronic Myeloid Leukemia - to follow
CLL: Chronic Lymphocytic Leukemia >
ET: Essential Thrombocythemia - to follow
MDS: Myelodysplastic Syndromes >
MPN: Myeloproliferative Neoplasms - to follow
Myelofibrosis - to follow

A selection of Our Key Questions

Can we identify risk profiles that predict clinical course and drug response?
What are the disease pathophysiology, disease course, and treatment outcomes?
How do molecular data relate to disease course and treatment response?
Can we harmonize the measurement of outcomes in trials?
Which rare side-effects can we observe in patients that are treated with hypomethylating agents?
Can we identify new outcomes to effectively evaluate the efficacy of new treatments after a shorter observation period?
Screen all the Key Questions for ALL, AML, CLL, CML, MDS, MPN >

Our Research Projects

Click here for an overview of current Research Projects in ALL, AML, CLL, CML, MDS, MPN and learn more about the challenge, envisioned impact and our experts involved >
More projects are expected to be published in the near future.
Link to press release about CLL research results at EHA2021 >
Link to press release about AML and CLL research results at ASH2021 >

Our Delphi Projects

What are Core Outcome Sets and Delphi Surveys and why do we need help from patients, clinicians, regulators and industry? Read more >
Click here to view which surveys are currenty open >

Our HARMONY Patient Organization Partners for ALL, AML, CLL, CML, MDS, MPN

Videos

#BigDataforBloodcancer: Tamás Bereczky, representing all HARMONY Patient Cluster Organizations through Leukanet, explains how we can help doctors treating blood cancer patients.

#BigDataforBloodcancer: Nick York, of CLL Advocates Network Healthcare Liaison Officer and leukaemia patient, explains HARMONY Delphi Surveys.

#BigDataforBloodcancer: Lars Bullinger, of Charité Berlin, explains news insights into Acute Myeloid Leukemia.

#BigDataforBloodcancer: Paolo Ghia, of European Research Initiative on CLL, explains about CLL and HARMONY.

We are currently interviewing Prof. Ghia to share the latest Big Data in CLL developments, stay tuned.

More?

Please make use of the search option on the top right of this page for more results on the topic of your interest.

Receive the latest news. Click here to subscribe!